Long-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib-Reference-Cited by-同舟云学术

Long-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib

Published:2018-09-02 Issue:4 Volume:183 Page:578-587
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Jain Preetesh¹²^ORCID,Kanagal-Shamanna Rashmi³,Zhang Shaojun⁴,Ahmed Makhdum⁵,Ghorab Ahmad⁵,Zhang Liang¹,Ok Chi Young³,Li Shaoying³,Hagemeister Frederick¹,Zeng Dongfeng¹,Gong Tiejun¹,Chen Wendy¹,Badillo Maria¹,Nomie Krystle¹,Fayad Luis¹,Medeiros Leonard J.³,Neelapu Sattva¹,Fowler Nathan¹,Romaguera Jorge¹^ORCID,Champlin Richard⁶,Wang Linghua⁴,Wang Michael L.¹

Affiliation:

1. Department of Lymphoma and Myeloma; the University of Texas MD Anderson Cancer Center; Houston TX USA

2. Division of Cancer Medicine; the University of Texas MD Anderson Cancer Center; Houston TX USA

3. Department of Hematopathology; the University of Texas MD Anderson Cancer Center; Houston TX USA

4. Department of Genomic Medicine; the University of Texas MD Anderson Cancer Center; Houston TX USA

5. Department of Leukemia; the University of Texas MD Anderson Cancer Center; Houston TX USA

6. Department of Stem cell transplant; the University of Texas MD Anderson Cancer Center; Houston TX USA

Funder

MD Anderson Cancer Center B Cell Lymphoma Moon Shot Program

Gary Rogers Foundation

Fox Family Foundation

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bjh.15567/fullpdf

Reference32 articles.

1. Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia;Ahn;Blood,2017

2. Expression of TP53 is associated with outcome of MCL independent of MIPI and Ki-67 in trials of the European-MCL network;Aukema;Blood,2018

3. Is there an increased rate of additional malignancies in patients with mantle cell lymphoma?;Barista;Annals of Oncology,2002

4. Landscape of somatic mutations and clonal evolution in mantle cell lymphoma;Bea;Proceedings of the National Academy of Sciences of the United States of America,2013

5. Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition;Burger;Nature Communications,2016

Cited by 90 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. From the archives of MD Anderson Cancer Center: Composite mantle cell lymphoma and lymphoplasmacytic lymphoma involving bone marrow at presentation;Annals of Diagnostic Pathology;2024-12

2. Dismantling relapsed/refractory mantle cell lymphoma;Blood Reviews;2024-09

3. Evaluating pirtobrutinib for the treatment of relapsed or refractory mantle cell lymphoma;Expert Review of Hematology;2024-08-08

4. PI3K inhibitor idelalisib enhances the anti-tumor effects of CDK4/6 inhibitor palbociclib via PLK1 in B-cell lymphoma;Cancer Letters;2024-08

5. Unmet needs in relapsed/refractory mantle cell lymphoma (r/r MCL) post-covalent Bruton tyrosine kinase inhibitor (BTKi): a systematic literature review and meta-analysis;Leukemia & Lymphoma;2024-07-08